Killing filarial nematode parasites: Role of treatment options and host immune response

Infectious Diseases of Poverty

Volumn 5, Issue 1, 2016, Pages

  Kwarteng, Alexander ^a,b   Ahuno, Samuel Terkper ^b   Akoto, Freda Osei ^b  

^a KUMASI CENTRE FOR COLLABORATIVE RESEARCH IN TROPICAL MEDICINE   (Ghana)

^b KWAME NKRUMAH UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Ghana)

Author keywords

Immune response; Ivermectin; Lymphatic filariasis; Onchocerciasis

Indexed keywords

ALBENDAZOLE; DOXYCYCLINE; IVERMECTIN; TRANSFORMING GROWTH FACTOR BETA; ANTIFILARIAL AGENT;

DISEASE TRANSMISSION; FILARIASIS; HUMAN; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; NONHUMAN; ONCHOCERCIASIS; PREVALENCE; PRIORITY JOURNAL; RESEARCH; REVIEW; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; ANIMAL; DRUG EFFECTS; FILARIOIDEA; IMMUNOLOGY; INNATE IMMUNITY; MICROFILARIA (NEMATODE LARVA); PARASITOLOGY;

ANIMALS; FILARIASIS; FILARICIDES; FILARIOIDEA; HUMANS; IMMUNITY, INNATE; MICROFILARIAE;

EID: 84989291087     PISSN: None     EISSN: 20499957     Source Type: Journal    
DOI: 10.1186/s40249-016-0183-0     Document Type: Review

References (42)

1. Saint Andre A, et al. The role of endosymbiotic Wolbachia bacteria in the pathogenesis of river blindness. Science. 2002;295(5561):1892-5.
2. Arndts K, et al. Elevated adaptive immune responses are associated with latent infections of Wuchereria bancrofti. PLoS Negl Trop Dis. 2012;6(4):e1611.
3. Arndts K, et al. Immunoepidemiological profiling of onchocerciasis patients reveals associations with microfilaria loads and ivermectin intake on both individual and community levels. PLoS Negl Trop Dis. 2014;8(2):e2679.
4. Simonsen PE, et al. The Filariases. 2014. p. 737-65. e5.
5. Taylor MJ, Hoerauf A, Bockarie M. Lymphatic filariasis and onchocerciasis. Lancet. 2010;376(9747):1175-85.
6. Geary TG, Moreno Y. Macrocyclic lactone anthelmintics: spectrum of activity and mechanism of action. Curr Pharm Biotechnol. 2012;13(6):866-72.
7. Rao UR, Chandrashekar R, Subrahmanyam D. Effect of ivermectin on serum dependent cellular interactions to Dipetalonema viteae microfilariae. Trop Med Parasitol. 1987;38(2):123-7.
8. Hoerauf A, et al. The variant Arg110Gln of human IL-13 is associated with an immunologically hyper-reactive form of onchocerciasis (sowda). Microbes Infect. 2002;4(1):37-42.
9. Debrah AY, et al. Transforming growth factor-beta1 variant Leu10Pro is associated with both lack of microfilariae and differential microfilarial loads in the blood of persons infected with lymphatic filariasis. Hum Immunol. 2011;72(11):1143-8.
10. Horton J. Albendazole: a review of anthelmintic efficacy and safety in humans. Parasitology. 2000;121(Suppl):S113-32.
11. Addiss D, et al. Albendazole for lymphatic filariasis. Cochrane Database Syst Rev. 2004;1:CD003753.
12. Meyrowitsch DW, Simonsen PE. Efficacy of DEC against Ascaris and hookworm infections in schoolchildren. Trop Med Int Health. 2001;6(9):739-42.
13. Peixoto CA, Silva BS. Anti-inflammatory effects of diethylcarbamazine: a review. Eur J Pharmacol. 2014;734:35-41.
14. Geary TG, et al. Unresolved issues in anthelmintic pharmacology for helminthiases of humans. Int J Parasitol. 2010;40(1):1-13.
15. Maizels RM, Denham DA. Diethylcarbamazine (DEC): immunopharmacological interactions of an anti-filarial drug. Parasitology. 1992;105(Suppl):S49-60.
16. Fernando SD, Rodrigo C, Rajapakse S. Current evidence on the use of antifilarial agents in the management of bancroftian filariasis. J Trop Med. 2011;2011:175941.
17. Osei-Atweneboana MY, et al. Prevalence and intensity of Onchocerca volvulus infection and efficacy of ivermectin in endemic communities in Ghana: a two-phase epidemiological study. Lancet. 2007;369(9578):2021-9.
18. Hoerauf A, et al. Doxycycline as a novel strategy against bancroftian filariasis-depletion of Wolbachia endosymbionts from Wuchereria bancrofti and stop of microfilaria production. Med Microbiol Immunol. 2003;192(4):211-6.
19. Hoerauf A, et al. Wolbachia endobacteria depletion by doxycycline as antifilarial therapy has macrofilaricidal activity in onchocerciasis: a randomized placebo-controlled study. Med Microbiol Immunol. 2008;197(3):295-311.
20. Specht S, et al. Efficacy of 2- and 4-week rifampicin treatment on the Wolbachia of Onchocerca volvulus. Parasitol Res. 2008;103(6):1303-9.
21. Mand S, et al. Doxycycline improves filarial lymphedema independent of active filarial infection: a randomized controlled trial. Clin Infect Dis. 2012;55(5):621-30.
22. Hoerauf A, et al. Filariasis in Africa--treatment challenges and prospects. Clin Microbiol Infect. 2011;17(7):977-85.
23. Debrah AY, et al. Doxycycline leads to sterility and enhanced killing of female onchocerca volvulus worms in an area with persistent microfilaridermia after repeated ivermectin treatment: a randomized, placebo-controlled. Double-Blind Trial Clin Infect Dis. 2015;61(4):517-26.
24. Osei-Atweneboana MY, et al. Phenotypic evidence of emerging ivermectin resistance in Onchocerca volvulus. PLoS Negl Trop Dis. 2011;5(3):e998.
25. Ravindran B, et al. Protective immunity in human lymphatic filariasis: problems and prospects. Med Microbiol Immunol. 2003;192(1):41-6.
26. Hise AG, Gillette-Ferguson I, Pearlman E. The role of endosymbiotic Wolbachia bacteria in filarial disease. Cell Microbiol. 2004;6(2):97-104.
27. Taylor MJ, Cross HF, Bilo K. Inflammatory responses induced by the filarial nematode Brugia malayi are mediated by lipopolysaccharide-like activity from endosymbiotic Wolbachia bacteria. J Exp Med. 2000;191(8):1429-36.
28. Dakshinamoorthy G, et al. Multivalent fusion protein vaccine for lymphatic filariasis. Vaccine. 2013;31(12):1616-22.
29. Specht S, et al. Lack of eosinophil peroxidase or major basic protein impairs defense against murine filarial infection. Infect Immun. 2006;74(9):5236-43.
30. Taylor MJ, et al. Susceptibility of Brugia malayi and Onchocerca lienalis microfilariae to nitric oxide and hydrogen peroxide in cell-free culture and from IFN gamma-activated macrophages. Parasitology. 1996;112(Pt 3):315-22.
31. Lawrence RA. Immunity to filarial nematodes. Vet Parasitol. 2001;100:33-44.
32. Katawa G, et al. Hyperreactive onchocerciasis is characterized by a combination of Th17-Th2 immune responses and reduced regulatory T cells. PLoS Negl Trop Dis. 2015;9(1):e3414.
33. Brattig NW. Pathogenesis and host responses in human onchocerciasis: impact of Onchocerca filariae and Wolbachia endobacteria. Microbes Infect. 2004;6(1):113-28.
34. Korten S, et al. Low levels of transforming growth factor-beta (TGF-beta) and reduced suppression of Th2-mediated inflammation in hyperreactive human onchocerciasis. Parasitology. 2011;138(1):35-45.
35. Hansen RD, et al. A worm’s best friend: recruitment of neutrophils by Wolbachia confounds eosinophil degranulation against the filarial nematode Onchocerca ochengi. Proc Biol Sci. 2011;278(1716):2293-302.
36. Capron M, et al. Eosinophil-dependent cytotoxicity in rat schistosomiasis. Involvement of IgG2a antibody and role of mast cells. Eur J Immunol. 1978;8(2):127-33.
37. Babayan SA, et al. Filarial parasites develop faster and reproduce earlier in response to host immune effectors that determine filarial life expectancy. PLoS Biol. 2010;8(10):e1000525.
38. Al-Qaoud KM, et al. A new mechanism for IL-5-dependent helminth control: neutrophil accumulation and neutrophil-mediated worm encapsulation in murine filariasis are abolished in the absence of IL-5. Int Immunol. 2000;12(6):899-908.
39. Torrero MN, et al. Basophils amplify type 2 immune responses, but do not serve a protective role, during chronic infection of mice with the filarial nematode Litomosoides sigmodontis. J Immunol. 2010;185(12):7426-34.
40. Sharma P, et al. Host lung immunity is severely compromised during tropical pulmonary eosinophilia: role of lung eosinophils and macrophages. J Leukoc Biol. 2016;99(4):619-28.
41. Kara EE, et al. Tailored immune responses: novel effector helper T cell subsets in protective immunity. PLoS Pathog. 2014;10(2):e1003905.
42. Semnani RT, Nutman TB. Toward an understanding of the interaction between filarial parasites and host antigen-presenting cells. Immunol Rev. 2004;201:127-38.